thalidomide has been researched along with Chloroma in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated sequential bortezomib, liposomal doxorubicin and dexamethasone (BDD) followed by thalidomide and dexamethasone (TD) if ≥ partial response (PR) or bortezomib and TD (BTD) if < PR in untreated patients with multiple myeloma with International Staging System stage II/III or extramedullary disease." | 9.16 | Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. ( Bello, C; Cohen, A; Comenzo, RL; Drullinsky, P; Hassoun, H; Hoover, E; Jhanwar, S; Landau, H; Lendvai, N; Lesokhin, A; Nimer, SD; Pandit-Taskar, N; Riedel, E; Schulman, P, 2012) |
| "We evaluated sequential bortezomib, liposomal doxorubicin and dexamethasone (BDD) followed by thalidomide and dexamethasone (TD) if ≥ partial response (PR) or bortezomib and TD (BTD) if < PR in untreated patients with multiple myeloma with International Staging System stage II/III or extramedullary disease." | 5.16 | Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. ( Bello, C; Cohen, A; Comenzo, RL; Drullinsky, P; Hassoun, H; Hoover, E; Jhanwar, S; Landau, H; Lendvai, N; Lesokhin, A; Nimer, SD; Pandit-Taskar, N; Riedel, E; Schulman, P, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mangiacavalli, S | 1 |
| Pompa, A | 1 |
| Ferretti, V | 1 |
| Klersy, C | 1 |
| Cocito, F | 1 |
| Varettoni, M | 1 |
| Cartia, CS | 1 |
| Cazzola, M | 1 |
| Corso, A | 1 |
| Yasuda, H | 1 |
| Ando, J | 1 |
| Sato, E | 1 |
| Inagaki, N | 1 |
| Aritaka, N | 1 |
| Komatsu, N | 1 |
| Hirano, T | 1 |
| Nakazato, T | 1 |
| Mihara, A | 1 |
| Ito, C | 1 |
| Sanada, Y | 1 |
| Aisa, Y | 1 |
| Landau, H | 1 |
| Pandit-Taskar, N | 1 |
| Hassoun, H | 1 |
| Cohen, A | 1 |
| Lesokhin, A | 1 |
| Lendvai, N | 1 |
| Drullinsky, P | 1 |
| Schulman, P | 1 |
| Jhanwar, S | 1 |
| Hoover, E | 1 |
| Bello, C | 1 |
| Riedel, E | 1 |
| Nimer, SD | 1 |
| Comenzo, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bortezomib + Pegylated Liposomal Doxorubicin (Doxil) + Dexamethasone Followed by Thalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone for Patients With Symptomatic Untreated High-Risk or Primary Resistant Multiple Myeloma[NCT00458705] | Phase 2 | 45 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The response of myeloma to BDDTD will be assessed by standard electrophoretic and immunofixation tests of blood and urine for a monoclonal protein (M protein), and bone marrow aspirate and biopsy. These tests will be performed at enrollment and at the conclusion of therapy. (NCT00458705)
Timeframe: 2 years
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Complete Response | Near Complete Response | Partial Response | Stable Disease | Progression of Disease | Very Good Partial Response | |
| Combination Therapy | 10 | 8 | 10 | 2 | 3 | 7 |
1 trial available for thalidomide and Chloroma
| Article | Year |
|---|---|
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2012 |
3 other studies available for thalidomide and Chloroma
| Article | Year |
|---|---|
The possible role of burden of therapy on the risk of myeloma extramedullary spread.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; | 2017 |
Successful treatment of extramedullary tumors with low-dose thalidomide in patients with multiple myeloma.
Topics: Aged; Dose-Response Relationship, Drug; Female; Humans; Multiple Myeloma; Sarcoma, Myeloid; Thalidom | 2010 |
Lenalidomide is active for extramedullary disease in refractory multiple myeloma.
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma | 2012 |